1. Home
  2. IMCR vs PRCH Comparison

IMCR vs PRCH Comparison

Compare IMCR & PRCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCR
  • PRCH
  • Stock Information
  • Founded
  • IMCR 2008
  • PRCH 2012
  • Country
  • IMCR United Kingdom
  • PRCH United States
  • Employees
  • IMCR N/A
  • PRCH N/A
  • Industry
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • PRCH Computer Software: Prepackaged Software
  • Sector
  • IMCR Health Care
  • PRCH Technology
  • Exchange
  • IMCR Nasdaq
  • PRCH Nasdaq
  • Market Cap
  • IMCR 1.7B
  • PRCH 2.0B
  • IPO Year
  • IMCR 2021
  • PRCH N/A
  • Fundamental
  • Price
  • IMCR $33.50
  • PRCH $16.50
  • Analyst Decision
  • IMCR Buy
  • PRCH Strong Buy
  • Analyst Count
  • IMCR 9
  • PRCH 10
  • Target Price
  • IMCR $62.38
  • PRCH $16.60
  • AVG Volume (30 Days)
  • IMCR 350.0K
  • PRCH 1.7M
  • Earning Date
  • IMCR 11-06-2025
  • PRCH 11-05-2025
  • Dividend Yield
  • IMCR N/A
  • PRCH N/A
  • EPS Growth
  • IMCR N/A
  • PRCH N/A
  • EPS
  • IMCR N/A
  • PRCH 0.52
  • Revenue
  • IMCR $356,145,000.00
  • PRCH $435,601,000.00
  • Revenue This Year
  • IMCR $29.99
  • PRCH N/A
  • Revenue Next Year
  • IMCR $8.85
  • PRCH $18.39
  • P/E Ratio
  • IMCR N/A
  • PRCH $31.43
  • Revenue Growth
  • IMCR 26.78
  • PRCH N/A
  • 52 Week Low
  • IMCR $23.15
  • PRCH $1.45
  • 52 Week High
  • IMCR $39.33
  • PRCH $19.44
  • Technical
  • Relative Strength Index (RSI)
  • IMCR 49.73
  • PRCH 54.19
  • Support Level
  • IMCR $31.36
  • PRCH $16.03
  • Resistance Level
  • IMCR $34.18
  • PRCH $16.76
  • Average True Range (ATR)
  • IMCR 1.38
  • PRCH 0.67
  • MACD
  • IMCR -0.00
  • PRCH 0.15
  • Stochastic Oscillator
  • IMCR 60.51
  • PRCH 88.17

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has two reportable segments: The vertical Software segment provides software and services to home services companies. The Vertical Software segment software and services provide inspection, mortgage, and title companies on a subscription and transactional basis, several key businesses, including inspection software and services, title insurance software, mortgage software, moving services, mover and homeowner marketing, and measurement software for roofers. The insurance segment provides consumers with insurance and warranty products to protect their homes, earning revenue through premiums collected on policies, policy fees, and commissions. Majority revenue is from Insurance segment.

Share on Social Networks: